AURORA trial
AURORA Trial
The AURORA Trial (pronounced: /əˈrɔːrə/ trial) is a significant medical research study that focuses on the treatment of lupus nephritis.
Etymology
The term 'AURORA' is an acronym that stands for "A Study to Evaluate the Efficacy and Safety of Voclosporin in Achieving Complete Remission in Subjects with Active Lupus Nephritis". The name 'AURORA' was chosen to symbolize the dawn of a new day in the treatment of lupus nephritis.
Overview
The AURORA Trial is a global, double-blind, placebo-controlled study that aims to evaluate the efficacy and safety of voclosporin in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids in subjects with active lupus nephritis. The trial was initiated by Aurinia Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need.
Related Terms
- Lupus Nephritis: A serious complication of systemic lupus erythematosus (SLE), a long-term autoimmune disease in which the body's immune system becomes hyperactive and attacks normal, healthy tissue.
- Voclosporin: An investigational drug that is being studied for its potential to treat patients with lupus nephritis.
- Mycophenolate Mofetil (MMF): An immunosuppressant drug used to prevent rejection in organ transplantation.
- Aurinia Pharmaceuticals: A biopharmaceutical company that initiated the AURORA trial.
External links
- Medical encyclopedia article on AURORA trial
- Wikipedia's article - AURORA trial
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski